Array Biopharma Inc (ARRY) 8.06 $ARRY
Early Briefing on Biotech Industry Stocks -- ARIAD Pharma, Array BioPharma, Rexahn Pharma, Inotek Pharma, and Neurocrine Biosciences
PR Newswire - Tue Mar 03, 7:40AM CST
Editor Note: For more information about this release, please scroll to bottom.
RNN: 0.75 (-0.02), NBIX: 40.67 (-0.25), ITEK: 6.00 (unch), ARIA: 8.08 (-0.17), ARRY: 8.06 (-0.18)
Array Announces Completion Of Binimetinib And Encorafenib Transactions
PR Newswire - Mon Mar 02, 7:00AM CST
Following announcements from both Novartis and GlaxoSmithKline regarding close of their transactions, Array BioPharma Inc. (NASDAQ: ARRY) today announced the completion of both the binimetinib and encorafenib definitive agreements with Novartis. Along with global ownership of both assets, Array will receive an upfront payment of $85 million from Novartis.
ARRY: 8.06 (-0.18), NVS: 97.46 (-1.49)
Investing In Precision Oncology: Targeting NTRK Genomic Alterations
Bay Area Biotech - at Seeking Alpha - Wed Feb 18, 10:44AM CST
LOXO: 13.79 (-0.56), TSRO: 55.11 (-0.10), RXDX: 7.58 (-0.27), PFE: 33.97 (-0.50), MRTX: 25.08 (-1.57), NVS: 97.46 (-1.49), ARRY: 8.06 (-0.18)
Array BioPharma Analyst Report: Pipeline Acquisition from Industry Partner Opens New Doors Issued by BrokerBank Securities, Inc.
PR Newswire - Tue Feb 17, 6:00AM CST
Array BioPharma Inc. (NASDAQ: ARRY) is a biopharmaceutical company, focusing on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. Array BioPharma Inc. was founded in 1998 with headquarter in Boulder, Colorado. The company's drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target pathways. The company's drug candidates include AMG 151, MEK162, ARRY-380, ARRY-520, ARRY-543 and ARRY-614.
ARRY: 8.06 (-0.18)
Oncolytics Seeks Orphan Drug Status for Reolysin in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 2:59PM CST
Oncolytics Biotech Inc. (ONCY) announced that it has submitted an application to FDA for obtaining orphan drug designation for Reolysin for the treatment of high-grade gliomas (HGG) in pediatric patients.
AGN: 233.51 (-1.90), BIIB: 417.63 (-7.98), ONCY: 0.90 (-0.15), ARRY: 8.06 (-0.18)
Why Array BioPharma Inc. Shares Skyrocketed 51% in January
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 06, 6:35AM CST
ARRY data by YCharts What: Shares of Array BioPharma , a biopharmaceutical company that's focused on developing novel drugs to fight cancer, skyrocketed by 51% in January, based on data from S&P Capital IQ , after announcing a pipeline...
NVS: 97.46 (-1.49), ARRY: 8.06 (-0.18)
Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
PR Newswire - Thu Feb 05, 11:30AM CST
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Leerink Swann Healthcare Conference in New York. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
ARRY: 8.06 (-0.18)
Array BioPharma's (ARRY) CEO Ron Squarer on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 03, 3:25PM CST
ARRY: 8.06 (-0.18)
Array BioPharma (ARRY) Q2 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Feb 03, 7:55AM CST
ARRY: 8.06 (-0.18)
Array BioPharma beats by $0.12, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 7:02AM CST
ARRY: 8.06 (-0.18)
Array Biopharma Reports Financial Results For The Second Quarter Of Fiscal 2015
PR Newswire - Tue Feb 03, 7:00AM CST
Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the second quarter of its fiscal year ending June 30, 2015.
ARRY: 8.06 (-0.18), NVS: 97.46 (-1.49)
Notable earnings before Tuesday’s open
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 4:30PM CST
CEVA: 19.93 (-0.09), HCLP: 34.65 (-0.98), PNR: 63.41 (-1.39), AET: 100.67 (-1.42), HW: 16.45 (-0.25), UPS: 100.62 (-0.10), NOV: 52.54 (-1.06), JLL: 155.07 (-4.51), ST: 55.99 (-0.99), LYB: 87.40 (-0.58), ACI: 1.10 (-0.02), R: 91.48 (-2.38), TECH: 97.48 (-0.33), SPR: 49.11 (-0.52), BP: 40.35 (-0.83), NYT: 13.40 (-0.13), WDR: 49.60 (-0.44), HRC: 47.82 (-0.51), MNK: 121.33 (-0.37), SC: 22.43 (+0.63), CHD: 83.77 (-1.49), ETN: 68.17 (-1.18), BHE: 23.36 (-0.33), ARG: 115.79 (-0.44), AGCO: 48.79 (-0.73), EMR: 56.56 (-1.52), GLPI: 32.37 (-1.17), CNC: 62.83 (-0.42), HCA: 72.82 (-0.09), MHO: 21.85 (-0.01), CARB: 14.60 (-0.15), AXE: 76.65 (-0.45), IMS: 25.81 (-0.46), GCI: 34.57 (-0.24), LPT: 35.03 (-1.16), CBR: 3.82 (-0.19), ARRY: 8.06 (-0.18), AN: 60.03 (-1.58)
Uptrend Call Working As Array Biopharma Stock Rises 93.5% (ARRY)
Comtex SmarTrend(R) - Mon Feb 02, 9:09AM CST
SmarTrend identified an Uptrend for Array Biopharma (NASDAQ:ARRY) on October 28th, 2014 at $3.71. In approximately 3 months, Array Biopharma has returned 93.52% as of today's recent price of $7.17.
ARRY: 8.06 (-0.18)
'Mad Money' Lightning Round: Alliant Techsystems Is Fabulous
at The Street - Fri Jan 30, 5:00AM CST
Cramer prefers Garmin to Trimble Navigation and recommends Kohlberg Kravis Roberts and Blackstone Group.
LMT: 197.66 (-1.44), BX: 38.75 (-0.39), TRMB: 26.10 (-0.25), NOC: 160.41 (-2.87), GRMN: 49.64 (-1.07), PPC: 26.43 (-0.76), JDSU: 13.89 (+0.57), TSN: 40.66 (+0.10), KKR: 23.71 (+0.04), ATK: 140.03 (+0.78), ARRY: 8.06 (-0.18)
Defense Stocks Are Fabulous - Cramer's Lightning Round (1/29/15)
SA Editor Mohit Manghnani - Seeking Alpha - Fri Jan 30, 4:30AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, January 29. Bullish Calls: Trimble Navigation (NASDAQ: TRMB ): "I do prefer Garmin (NASDAQ: GRMN ) if you want to be in that game." KKR...
LMT: 197.66 (-1.44), BX: 38.75 (-0.39), TRMB: 26.10 (-0.25), MDCO: 28.78 (-0.86), NOC: 160.41 (-2.87), GRMN: 49.64 (-1.07), JDSU: 13.89 (+0.57), PPC: 26.43 (-0.76), TSN: 40.66 (+0.10), KKR: 23.71 (+0.04), ATK: 140.03 (+0.78), MTW: 21.30 (-1.00), ARRY: 8.06 (-0.18)
Jim Cramer's 'Mad Money' Recap: The Bears Retreat and the Market Celebrates
at The Street - Thu Jan 29, 7:19PM CST
Today was a terrific snap-back rally, a day when the bears retreated and calmer heads could take advantage of all the positives that go unappreciated on most days, Cramer says.
LMT: 197.66 (-1.44), BX: 38.75 (-0.39), FB: 80.00 (-1.21), NOC: 160.41 (-2.87), GRMN: 49.64 (-1.07), TSN: 40.66 (+0.10), KKR: 23.71 (+0.04), ATK: 140.03 (+0.78), BA: 153.12 (-1.35), CLB: 109.53 (-3.64), SBUX: 92.21 (-1.42), RDUS: 47.47 (+1.29), TRMB: 26.10 (-0.25), PHM: 21.22 (-1.02), PPC: 26.43 (-0.76), JDSU: 13.89 (+0.57), MCD: 97.13 (-1.98), ARRY: 8.06 (-0.18)
Earnings Peek: Array BioPharma Has A Lot Going On, And A Lot Of Money
Clinically Sound Investor - at Seeking Alpha - Wed Jan 28, 9:18AM CST
ARRY: 8.06 (-0.18)
Does This 50% Price Target Hike For Array BioPharma Inc. Make Sense?
Sean Williams, The Motley Fool - Motley Fool - Tue Jan 27, 8:51AM CST
What: Shares of Array BioPharma , a biopharmaceutical company focused on developing novel small molecule cancer drugs, surged just shy of 10% on Monday following a hefty price target hike from brokerage firm Stifel Nicolaus. So what: Stifel...
NVS: 97.46 (-1.49), ARRY: 8.06 (-0.18)
Array BioPharma (ARRY) Jumps: Stock Adds 9.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 27, 7:51AM CST
Array BioPharma, Inc. (ARRY) was a big mover last session, as the company saw its shares rise by almost 10% on the day.
AMAG: 51.58 (+0.19), ARRY: 8.06 (-0.18)
Biotech Stocks Technical Analysis - Achillion Pharma, Array BioPharma, Rexahn Pharma, Neurocrine Biosciences, and Bluebird Bio
PR Newswire - Tue Jan 27, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Array BioPharma Inc. (NASDAQ: ARRY), Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Bluebird Bio Inc. (NASDAQ: BLUE). Free research report on Achillion Pharma can be accessed at http://get.Investor-Edge.com/pdf/?c=Achillion...amp;s=ACHN. On Monday, January 26, 2015, the NASDAQ Composite ended at 4,771.76, up 0.29%, the Dow Jones Industrial Average advanced 0.03%, to finish the day at 17,678.70, and the S&P 500 closed at 2,057.09, up 0.26%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 825.01, up 0.45%, with the index also advancing 9.36% in the previous three months. Register for your complimentary reports at the links given below.
BLUE: 113.14 (+0.91), RNN: 0.75 (-0.02), NBIX: 40.67 (-0.25), ACHN: 11.39 (+0.40), ARRY: 8.06 (-0.18)
Early Briefing on Biotech Industry Stocks -- ARIAD Pharma, Array BioPharma, Rexahn Pharma, Inotek Pharma, and Neurocrine Biosciences
PR Newswire - Tue Mar 03, 7:40AM CST
Editor Note: For more information about this release, please scroll to bottom.
RNN: 0.75 (-0.02), NBIX: 40.67 (-0.25), ITEK: 6.00 (unch), ARIA: 8.08 (-0.17), ARRY: 8.06 (-0.18)
Array Announces Completion Of Binimetinib And Encorafenib Transactions
PR Newswire - Mon Mar 02, 7:00AM CST
Following announcements from both Novartis and GlaxoSmithKline regarding close of their transactions, Array BioPharma Inc. (NASDAQ: ARRY) today announced the completion of both the binimetinib and encorafenib definitive agreements with Novartis. Along with global ownership of both assets, Array will receive an upfront payment of $85 million from Novartis.
ARRY: 8.06 (-0.18), NVS: 97.46 (-1.49)
Investing In Precision Oncology: Targeting NTRK Genomic Alterations
Bay Area Biotech - at Seeking Alpha - Wed Feb 18, 10:44AM CST
LOXO: 13.79 (-0.56), TSRO: 55.11 (-0.10), RXDX: 7.58 (-0.27), PFE: 33.97 (-0.50), MRTX: 25.08 (-1.57), NVS: 97.46 (-1.49), ARRY: 8.06 (-0.18)
Array BioPharma Analyst Report: Pipeline Acquisition from Industry Partner Opens New Doors Issued by BrokerBank Securities, Inc.
PR Newswire - Tue Feb 17, 6:00AM CST
Array BioPharma Inc. (NASDAQ: ARRY) is a biopharmaceutical company, focusing on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. Array BioPharma Inc. was founded in 1998 with headquarter in Boulder, Colorado. The company's drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target pathways. The company's drug candidates include AMG 151, MEK162, ARRY-380, ARRY-520, ARRY-543 and ARRY-614.
ARRY: 8.06 (-0.18)
Oncolytics Seeks Orphan Drug Status for Reolysin in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 2:59PM CST
Oncolytics Biotech Inc. (ONCY) announced that it has submitted an application to FDA for obtaining orphan drug designation for Reolysin for the treatment of high-grade gliomas (HGG) in pediatric patients.
AGN: 233.51 (-1.90), BIIB: 417.63 (-7.98), ONCY: 0.90 (-0.15), ARRY: 8.06 (-0.18)
Why Array BioPharma Inc. Shares Skyrocketed 51% in January
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 06, 6:35AM CST
ARRY data by YCharts What: Shares of Array BioPharma , a biopharmaceutical company that's focused on developing novel drugs to fight cancer, skyrocketed by 51% in January, based on data from S&P Capital IQ , after announcing a pipeline...
NVS: 97.46 (-1.49), ARRY: 8.06 (-0.18)
Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
PR Newswire - Thu Feb 05, 11:30AM CST
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Leerink Swann Healthcare Conference in New York. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
ARRY: 8.06 (-0.18)
Array BioPharma's (ARRY) CEO Ron Squarer on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 03, 3:25PM CST
ARRY: 8.06 (-0.18)
Array BioPharma (ARRY) Q2 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Feb 03, 7:55AM CST
ARRY: 8.06 (-0.18)
Array BioPharma beats by $0.12, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 7:02AM CST
ARRY: 8.06 (-0.18)
Array Biopharma Reports Financial Results For The Second Quarter Of Fiscal 2015
PR Newswire - Tue Feb 03, 7:00AM CST
Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the second quarter of its fiscal year ending June 30, 2015.
ARRY: 8.06 (-0.18), NVS: 97.46 (-1.49)
Notable earnings before Tuesday’s open
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 4:30PM CST
CEVA: 19.93 (-0.09), HCLP: 34.65 (-0.98), PNR: 63.41 (-1.39), AET: 100.67 (-1.42), HW: 16.45 (-0.25), UPS: 100.62 (-0.10), NOV: 52.54 (-1.06), JLL: 155.07 (-4.51), ST: 55.99 (-0.99), LYB: 87.40 (-0.58), ACI: 1.10 (-0.02), R: 91.48 (-2.38), TECH: 97.48 (-0.33), SPR: 49.11 (-0.52), BP: 40.35 (-0.83), NYT: 13.40 (-0.13), WDR: 49.60 (-0.44), HRC: 47.82 (-0.51), MNK: 121.33 (-0.37), SC: 22.43 (+0.63), CHD: 83.77 (-1.49), ETN: 68.17 (-1.18), BHE: 23.36 (-0.33), ARG: 115.79 (-0.44), AGCO: 48.79 (-0.73), EMR: 56.56 (-1.52), GLPI: 32.37 (-1.17), CNC: 62.83 (-0.42), HCA: 72.82 (-0.09), MHO: 21.85 (-0.01), CARB: 14.60 (-0.15), AXE: 76.65 (-0.45), IMS: 25.81 (-0.46), GCI: 34.57 (-0.24), LPT: 35.03 (-1.16), CBR: 3.82 (-0.19), ARRY: 8.06 (-0.18), AN: 60.03 (-1.58)
Uptrend Call Working As Array Biopharma Stock Rises 93.5% (ARRY)
Comtex SmarTrend(R) - Mon Feb 02, 9:09AM CST
SmarTrend identified an Uptrend for Array Biopharma (NASDAQ:ARRY) on October 28th, 2014 at $3.71. In approximately 3 months, Array Biopharma has returned 93.52% as of today's recent price of $7.17.
ARRY: 8.06 (-0.18)
'Mad Money' Lightning Round: Alliant Techsystems Is Fabulous
at The Street - Fri Jan 30, 5:00AM CST
Cramer prefers Garmin to Trimble Navigation and recommends Kohlberg Kravis Roberts and Blackstone Group.
LMT: 197.66 (-1.44), BX: 38.75 (-0.39), TRMB: 26.10 (-0.25), NOC: 160.41 (-2.87), GRMN: 49.64 (-1.07), PPC: 26.43 (-0.76), JDSU: 13.89 (+0.57), TSN: 40.66 (+0.10), KKR: 23.71 (+0.04), ATK: 140.03 (+0.78), ARRY: 8.06 (-0.18)
Defense Stocks Are Fabulous - Cramer's Lightning Round (1/29/15)
SA Editor Mohit Manghnani - Seeking Alpha - Fri Jan 30, 4:30AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, January 29. Bullish Calls: Trimble Navigation (NASDAQ: TRMB ): "I do prefer Garmin (NASDAQ: GRMN ) if you want to be in that game." KKR...
LMT: 197.66 (-1.44), BX: 38.75 (-0.39), TRMB: 26.10 (-0.25), MDCO: 28.78 (-0.86), NOC: 160.41 (-2.87), GRMN: 49.64 (-1.07), JDSU: 13.89 (+0.57), PPC: 26.43 (-0.76), TSN: 40.66 (+0.10), KKR: 23.71 (+0.04), ATK: 140.03 (+0.78), MTW: 21.30 (-1.00), ARRY: 8.06 (-0.18)
Jim Cramer's 'Mad Money' Recap: The Bears Retreat and the Market Celebrates
at The Street - Thu Jan 29, 7:19PM CST
Today was a terrific snap-back rally, a day when the bears retreated and calmer heads could take advantage of all the positives that go unappreciated on most days, Cramer says.
LMT: 197.66 (-1.44), BX: 38.75 (-0.39), FB: 80.00 (-1.21), NOC: 160.41 (-2.87), GRMN: 49.64 (-1.07), TSN: 40.66 (+0.10), KKR: 23.71 (+0.04), ATK: 140.03 (+0.78), BA: 153.12 (-1.35), CLB: 109.53 (-3.64), SBUX: 92.21 (-1.42), RDUS: 47.47 (+1.29), TRMB: 26.10 (-0.25), PHM: 21.22 (-1.02), PPC: 26.43 (-0.76), JDSU: 13.89 (+0.57), MCD: 97.13 (-1.98), ARRY: 8.06 (-0.18)
Earnings Peek: Array BioPharma Has A Lot Going On, And A Lot Of Money
Clinically Sound Investor - at Seeking Alpha - Wed Jan 28, 9:18AM CST
ARRY: 8.06 (-0.18)
Does This 50% Price Target Hike For Array BioPharma Inc. Make Sense?
Sean Williams, The Motley Fool - Motley Fool - Tue Jan 27, 8:51AM CST
What: Shares of Array BioPharma , a biopharmaceutical company focused on developing novel small molecule cancer drugs, surged just shy of 10% on Monday following a hefty price target hike from brokerage firm Stifel Nicolaus. So what: Stifel...
NVS: 97.46 (-1.49), ARRY: 8.06 (-0.18)
Array BioPharma (ARRY) Jumps: Stock Adds 9.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 27, 7:51AM CST
Array BioPharma, Inc. (ARRY) was a big mover last session, as the company saw its shares rise by almost 10% on the day.
AMAG: 51.58 (+0.19), ARRY: 8.06 (-0.18)
Biotech Stocks Technical Analysis - Achillion Pharma, Array BioPharma, Rexahn Pharma, Neurocrine Biosciences, and Bluebird Bio
PR Newswire - Tue Jan 27, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Array BioPharma Inc. (NASDAQ: ARRY), Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Bluebird Bio Inc. (NASDAQ: BLUE). Free research report on Achillion Pharma can be accessed at http://get.Investor-Edge.com/pdf/?c=Achillion...amp;s=ACHN. On Monday, January 26, 2015, the NASDAQ Composite ended at 4,771.76, up 0.29%, the Dow Jones Industrial Average advanced 0.03%, to finish the day at 17,678.70, and the S&P 500 closed at 2,057.09, up 0.26%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 825.01, up 0.45%, with the index also advancing 9.36% in the previous three months. Register for your complimentary reports at the links given below.
BLUE: 113.14 (+0.91), RNN: 0.75 (-0.02), NBIX: 40.67 (-0.25), ACHN: 11.39 (+0.40), ARRY: 8.06 (-0.18)
